Fed. Circ. Keeps PTAB Ax Of Purdue OxyContin Patent Claims
The Federal Circuit Wednesday affirmed Patent Trial and Appeal Board decisions that invalidate, as obvious, many claims of a Purdue Pharma patent on extended-release formulations of OxyContin designed to deter abuse....To view the full article, register now.
Already a subscriber? Click here to view full article